WallStSmart

Abbott Laboratories (ABT)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 126% more annual revenue ($46.59B vs $20.61B). BSX leads profitability with a 17.3% profit margin vs 11.7%. BSX appears more attractively valued with a PEG of 0.54. BSX earns a higher WallStSmart Score of 76/100 (B+).

ABT

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

BSX

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 5/9Altman Z: 1.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$73.35

Current Price

$105.64

$32.29 premium

UndervaluedFair: $73.35Overvalued
BSXSignificantly Overvalued (-23.2%)

Margin of Safety

-23.2%

Fair Value

$37.36

Current Price

$47.75

$10.39 premium

UndervaluedFair: $37.36Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$177.07B9/10

Large-cap with strong market position

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$63.87B9/10

Large-cap with strong market position

PEG RatioValuation
0.548/10

Growing faster than its price suggests

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
2.014/10

Expensive relative to growth rate

P/E RatioValuation
32.2x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Key Dynamics to Monitor

ABT profiles as a value stock while BSX is a mature play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.61 — expect wider price swings.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (76/100 vs 52/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?